AhR Agonist Program
Ulcerative Colitis
Key Facts
About Azora Therapeutics
Azora Therapeutics is a private, pre-revenue biotech leveraging the aryl hydrocarbon receptor (AhR) pathway to develop localized small molecule therapies for inflammatory diseases. The company has a clinical-stage program, evidenced by a published Phase 1b study in ulcerative colitis, and is built by a team with significant prior drug development experience. Its strategy focuses on addressing serious conditions like hidradenitis suppurativa and ulcerative colitis by targeting a fundamental immune regulatory mechanism with potential for improved safety and efficacy.
View full company profileAbout Azora Therapeutics
Azora Therapeutics is a private, pre-revenue biotech leveraging the aryl hydrocarbon receptor (AhR) pathway to develop localized small molecule therapies for inflammatory diseases. The company has a clinical-stage program, evidenced by a published Phase 1b study in ulcerative colitis, and is built by a team with significant prior drug development experience. Its strategy focuses on addressing serious conditions like hidradenitis suppurativa and ulcerative colitis by targeting a fundamental immune regulatory mechanism with potential for improved safety and efficacy.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| BB265 | BiomeBank | Phase 1 |
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |
| '1805 | Revolo Biotherapeutics | Phase 2 (Planned) |